Rifampicin Regimen for Hansen Disease in India
For multibacillary (MB) leprosy in India, the modified regimen of rifampicin 600 mg daily for 21 days followed by standard WHO monthly multidrug therapy (MDT) is highly effective and achieves faster bacteriological clearance than monthly rifampicin alone, though both approaches are acceptable.
Evidence-Based Rationale
The Indian Association of Leprologists developed a modified MDT regimen specifically addressing the need for rapid reduction in bacterial load and infectivity. This approach combines:
- Initial intensive phase: Rifampicin 600 mg + clofazimine 100 mg + dapsone 100 mg daily for 21 days
- Continuation phase: Standard WHO monthly supervised rifampicin 600 mg + clofazimine 300 mg, with daily self-administered dapsone 100 mg and clofazimine 100 mg on alternate days
Key Clinical Advantages
The modified regimen demonstrated significantly faster decline in morphological index compared to standard WHO MDT in controlled trials 1. This translates to:
- More rapid reduction in infectivity
- Faster clinical improvement in multibacillary cases
- Maintained safety profile without additional adverse effects beyond expected skin pigmentation from clofazimine
Alternative Monthly Rifampicin Approach
If the 21-day intensive regimen is not feasible, once-monthly rifampicin 1200 mg combined with daily dapsone and clofazimine remains highly effective 2, 3, 4. This schedule:
- Costs approximately one-tenth of daily rifampicin regimens
- Allows supervised administration
- Shows equivalent bacteriological regression over 6 months
- Does NOT cause flu syndrome, hemolytic anemia, or renal complications when given monthly (unlike intermittent twice-weekly dosing which carries these risks) 5
Critical Safety Considerations
Avoid intermittent twice-weekly rifampicin dosing >600 mg - this causes severe adverse reactions including flu syndrome, hemolytic anemia, thrombocytopenia, and renal failure 5. Monthly or daily dosing is safe; twice-weekly is dangerous.
Drug Interactions to Monitor
Rifampicin is a potent enzyme inducer 5:
- Oral contraceptives: Add barrier contraception methods
- Warfarin: Monitor INR closely; may need 2-3 fold dose increase
- Diabetes medications: Glucose control may worsen; monitor closely
- Corticosteroids (for leprosy reactions): May require 2-3 fold dose increase
Treatment Duration
- Multibacillary leprosy: 12 months minimum of MDT
- Paucibacillary leprosy: 6 months of MDT
Monitoring Parameters
- Baseline and periodic liver function tests (rifampicin can cause transient elevations) 5
- Skin smear bacterial and morphological indices
- Clinical assessment for leprosy reactions (Type 1 and Type 2)
- Nerve function testing for early detection of neuropathy
Common Pitfalls
Do not discontinue treatment prematurely - even if patients feel better early in therapy, incomplete treatment increases resistance risk and relapse rates 5. The modified 21-day intensive phase does NOT replace the full 12-month MDT course; it supplements it.
Warn patients about harmless pigmentation changes - rifampicin causes orange-red discoloration of urine, sweat, tears, and can permanently stain contact lenses 5. This is expected and not harmful.
Manage leprosy reactions aggressively - continue MDT while treating reactions with corticosteroids or thalidomide (where available). Stopping MDT during reactions worsens outcomes 6.